Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS1805
- Development stage
- Phase 1
- Lead developer
- Reistone Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RS1805 is a potent and highly selective small molecule inhibitor of Janus kinase 1 (JAK1) developed by Rui Stone Biopharmaceutical for the treatment of inflammatory bowel diseases, specifically ulcerative colitis. By selectively targeting the JAK1 isoform over JAK2, JAK3, and TYK2, RS1805 aims to modulate the signaling pathways of key pro-inflammatory cytokines, such as interleukin-6 (IL-6) and interferon-gamma (IFN-γ), while minimizing off-target effects associated with broader JAK inhibition, such as anemia or neutropenia. The drug is designed for oral administration and is currently being evaluated in Phase 2 clinical trials to determine its efficacy and safety in patients with moderate-to-severe active ulcerative colitis.
02
Targets
Beyond the preview
Go deeper on RS1805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS1805.